# US 2021/0332132 A1 · Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332132 A1
- Document ID: US20210332132A1
- Status: Published application
- Kind: A1
- Application number: 17/367,133
- Filed: 2021-07-02
- Published: 2021-10-28
- Earliest claimed: 2013-07-16
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Jane Grogan; Robert J. Johnston; Bryan Irving; Jason Hackney; Xin Yu; Dan Eaton; Kristin Bowles; Laetitia Comps-Agrar
- Web page: https://patentgrep.com/patent/US20210332132A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A01K 67/0276: Knock-out vertebrates
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/3015: {Breast}
- C07K 16/3023: {Lung}
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3038: {Kidney, bladder}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3053: {Skin, nerves, brain}
- C07K 16/3061: {Blood cells}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- A01K 2267/0387: Animal model for diseases of the immune system
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

## Claims

### Claim at position 1

-166. (canceled)

### Claim 167

A method of treating cancer in a human subject in need thereof, comprising administering to the human subject an effective amount of:
a. an anti-PD-L1 antagonistic antibody; and
b. an anti-TIGIT antagonistic antibody.

### Claim 168 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is a human antibody or a humanized antibody.

### Claim 169 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is a monoclonal antibody.

### Claim 170 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is a monoclonal humanized antibody.

### Claim 171 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is a monoclonal human antibody.

### Claim 172 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is an IgG antibody.

### Claim 173 (depends on 172)

The method of claim 172, wherein the anti-TIGIT antagonistic antibody is an IgG-1 antibody.

### Claim 174 (depends on 173)

The method of claim 173, wherein the anti-TIGIT antagonistic antibody is a monoclonal human IgG-1 antibody or a monoclonal humanized IgG-1 antibody.

### Claim 175 (depends on 172)

The method of claim 172, wherein the anti-TIGIT antagonistic antibody is an IgG-4 antibody.

### Claim 176 (depends on 175)

The method of claim 175, wherein the anti-TIGIT antagonistic antibody is a monoclonal human IgG-4 antibody or a monoclonal humanized IgG-4 antibody.

### Claim 177 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody comprises a heavy chain comprising a HVR-H1 sequence of GFTFSDSWTH (SEQ ID NO: 17), a HVR-H2 sequence of AWISPYGGSTYYADSVKG (SEQ ID NO: 18), and a HVR-H3 sequence of RHWPGGFDY (SEQ ID NO: 19); and a light chain comprising a HVR-L1 sequence of RASQDVSTAVA (SEQ ID NO:20), a HVR-L2 sequence of SASFLYS (SEQ ID NO:21), and a HVR-L3 sequence of QQYLYHPAT (SEQ ID NO:22).

### Claim 178 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody is MEDI4736.

### Claim 179 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody is a human antibody or a humanized antibody.

### Claim 180 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody is a monoclonal antibody.

### Claim 181 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody is a monoclonal humanized antibody.

### Claim 182 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody is a monoclonal human antibody.

### Claim 183 (depends on 167)

The method of claim 167, wherein the anti-PD-L1 antagonistic antibody is an IgG antibody.

### Claim 184 (depends on 183)

The method of claim 183, wherein the anti-PD-L1 antagonistic antibody is an IgG-1 antibody.

### Claim 185 (depends on 184)

The method of claim 184, wherein the anti-PD-L1 antagonistic antibody is a monoclonal human IgG-1 antibody or a monoclonal humanized IgG-1 antibody.

### Claim 186 (depends on 183)

The method of claim 183, wherein the anti-PD-L1 antagonistic antibody is an IgG-4 antibody.

### Claim 187 (depends on 186)

The method of claim 186, wherein the anti-PD-L1 antagonistic antibody is a monoclonal human IgG-4 antibody or a monoclonal humanized IgG-4 antibody.

### Claim 188 (depends on 167)

The method of claim 167, further comprising administering an effective amount of at least one chemotherapeutic agent.

### Claim 189 (depends on 167)

The method of claim 167, wherein the cancer is selected from the group consisting of a non-small cell lung cancer, a small cell lung cancer, a renal cell cancer, a colorectal cancer, an ovarian cancer, a breast cancer, a pancreatic cancer, a gastric carcinoma, a bladder cancer, an esophageal cancer, a mesothelioma, a melanoma, a head and neck cancer, a thyroid cancer, a sarcoma, a prostate cancer, a glioblastoma, a cervical cancer, a thymic carcinoma, a leukemia, a lymphoma, a myeloma, a mycosis fungoides, a Merkel cell cancer, and a hematologic malignancy.

### Claim 190 (depends on 167)

The method of claim 167, wherein the cancer is selected from the group consisting of a non-small cell lung cancer, a small cell lung cancer, a hepatocellular cancer, a renal cell cancer, a head and neck cancer, a colorectal cancer, a breast cancer, an esophageal cancer, a gastric carcinoma, a cervical cancer, an endometrial cancer, a bladder cancer, a melanoma, a lymphoma, and a Merkel cell cancer.

### Claim 191 (depends on 167)

The method of claim 167, wherein the cancer is melanoma.

### Claim 192 (depends on 167)

The method of claim 167, wherein the cancer is non-small cell lung cancer.

### Claim 193 (depends on 167)

The method of claim 167, wherein the cancer is a solid tumor.

### Claim 194 (depends on 167)

The method of claim 167, wherein the cancer is a hematologic malignancy.

### Claim 195 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is administered before or after the anti-PD-L1 antagonistic antibody.

### Claim 196 (depends on 167)

The method of claim 167, wherein the anti-TIGIT antagonistic antibody is administered simultaneously with the anti-PD-L1 antagonistic antibody.
